Boundless Bio Raises Oversubscribed $105 Million Series B Financing To Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal Dna (Ecdna)
Boundless Bio Raises Oversubscribed $105 Million Series B Financing To Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal Dna (Ecdna)
04/28/21, 11:36 AM
Location
Money raised
$105 million
Round Type
series b
Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHOTM) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.
Company Info
Location
san diego, california, united states
Additional Info
Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.